Ozempic, manufactured by Novo Nordisk, gains EMA approval for chronic kidney disease, reducing disease progression by 24%, per the Flow trial. With 40% of type 2...
Vertex announced plans to acquire Alpine Immune Sciences for $4.9 billion, primarily for its experimental drug povetacicept to treat IgA nephropathy. Vertex will pay $65 per...